Literature DB >> 19688335

Collateral damage: the conundrum of drug safety.

E A M Gale.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19688335     DOI： 10.1007/s00125-009-1491-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  21 in total

Review 1.  Detection, verification, and quantification of adverse drug reactions.

Authors:  Bruno H Ch Stricker; Bruce M Psaty
Journal:  BMJ       Date:  2004-07-03

2.  Troglitazone: the lesson that nobody learned?

Authors:  Edwin A M Gale
Journal:  Diabetologia       Date:  2006-01       Impact factor: 10.122

3.  Opening Pandora's pillbox: using modern information tools to improve drug safety.

Authors:  Scott Gottlieb
Journal:  Health Aff (Millwood)       Date:  2005 Jul-Aug       Impact factor: 6.301

4.  Exenatide (exendin-4)-induced pancreatitis: a case report.

Authors:  Paul S Denker; Paul E Dimarco
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

5.  Finding new treatments for diabetes--how many, how fast... how good?

Authors:  David M Nathan
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

6.  Time to act on drug safety.

Authors:  T J Moore; B M Psaty; C D Furberg
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

7.  Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

Authors:  David D Dore; John D Seeger; K Arnold Chan
Journal:  Curr Med Res Opin       Date:  2009-04       Impact factor: 2.580

8.  Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2008-10-22       Impact factor: 10.122

9.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

10.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122
View more
  8 in total

1.  Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?

Authors:  Christoph Schindler
Journal:  Ther Adv Endocrinol Metab       Date:  2011-12       Impact factor: 3.565

2.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Authors:  Michael Elashoff; Aleksey V Matveyenko; Belinda Gier; Robert Elashoff; Peter C Butler
Journal:  Gastroenterology       Date:  2011-02-18       Impact factor: 22.682

3.  Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis.

Authors:  Asha Krishnan; Derrick J Stobaugh; Parakkal Deepak
Journal:  Rheumatol Int       Date:  2014-09-17       Impact factor: 2.631

4.  It's time to mow the GRAS in type 1 diabetes.

Authors:  Desmond A Schatz; S Robert Levine; Mark A Atkinson
Journal:  Diabetes       Date:  2011-11       Impact factor: 9.461

5.  GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?

Authors:  Edwin A M Gale
Journal:  Diabetes       Date:  2012-05       Impact factor: 9.461

6.  Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  Ming Zhao; Jiayi Chen; Yanyan Yuan; Zuquan Zou; Xiaolong Lai; Daud M Rahmani; Fuyan Wang; Yang Xi; Qin Huang; Shizhong Bu
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

7.  Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

Authors:  P C Butler; A V Matveyenko; S Dry; A Bhushan; R Elashoff
Journal:  Diabetologia       Date:  2009-11-06       Impact factor: 10.122

8.  A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

Authors:  Peter C Butler; Michael Elashoff; Robert Elashoff; Edwin A M Gale
Journal:  Diabetes Care       Date:  2013-05-03       Impact factor: 19.112
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.